---
title: "Lucid Diagnostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.256 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286413447.md"
datetime: "2026-05-14T12:07:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286413447.md)
  - [en](https://longbridge.com/en/news/286413447.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286413447.md)
---

# Lucid Diagnostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.256 M

Revenue: As of FY2026 Q1, the actual value is USD 1.256 M, missing the estimate of USD 1.383 M.

EPS: As of FY2026 Q1, the actual value is USD -0.17, missing the estimate of USD -0.085.

EBIT: As of FY2026 Q1, the actual value is USD -12.18 M.

#### Revenue

-   For the three months ended March 31, 2026, EsoGuard related revenues were $1.3 million. Revenue was $1,256 thousand for the three months ended March 31, 2026, compared to $828 thousand for the same period in 2025.

#### Operating Expenses

-   Operating expenses were approximately $13.4 million for the three months ended March 31, 2026, which included stock-based compensation expenses of $1.4 million. Total operating expenses were $13,370 thousand for the three months ended March 31, 2026, compared to $13,315 thousand for the same period in 2025. Net operating expenses were $11,708 thousand for the three months ended March 31, 2026, compared to $11,990 thousand for the same period in 2025.

#### Other (Income) Expense, Net

-   Other (Income) expense, net was $1,795 thousand for the three months ended March 31, 2026, compared to $14,421 thousand for the same period in 2025.

#### Net Loss

-   GAAP net loss attributable to common stockholders was approximately - $23.6 million for the three months ended March 31, 2026, inclusive of a deemed Preferred Stock dividend of $9.7 million or - $0.17 per common share. Net Loss was - $13,909 thousand for the three months ended March 31, 2026, compared to - $26,908 thousand for the same period in 2025. Net loss attributable to common stockholders was - $23,628 thousand for the three months ended March 31, 2026, compared to - $36,018 thousand for the same period in 2025.

#### Non-GAAP Adjusted Loss

-   The non-GAAP adjusted loss for the three months ended March 31, 2026, was approximately - $10.5 million or - $0.07 per common share. Non-GAAP adjusted (loss) was - $10,452 thousand for the three months ended March 31, 2026, compared to - $11,162 thousand for the same period in 2025.

#### Cash and Cash Equivalents

-   Lucid Diagnostics Inc. had cash and cash equivalents of $27.9 million as of March 31, 2026, compared to $34.7 million as of December 31, 2025. The company ended Q1 2026 with $45 million in proforma cash, extending its runway into 2027.

#### Operational Metrics

-   Lucid Diagnostics Inc. processed 3,177 EsoGuard® tests in Q1 2026.

#### Outlook / Guidance

-   Lucid Diagnostics Inc. aims to build commercial momentum for EsoGuard by generating consistent demand and progressing Medicare and VA targeting efforts. The company plans to expand engagement with health systems and commercial payors. This strategy positions Lucid Diagnostics Inc. to convert EsoGuard demand to revenue and accelerate commercialization as key reimbursement milestones are achieved.

### Related Stocks

- [LUCD.US](https://longbridge.com/en/quote/LUCD.US.md)

## Related News & Research

- [Lucid Diagnostics Reports Q1 2026 Results and Outlook](https://longbridge.com/en/news/286419963.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)